Genemod Raises $1.7M in Oversubscribed Seed Round to Drive the Next Generation of Medicine
Summary
By streamlining inventory, experiment, application and data management, Genemod helps scientists conduct repeatable research and develop cures faster. Todays funding will allow Genemod to grow its current headcount by 50 percent and expand its customer base beyond academic institutions and into small enterprises. "While the life sciences industry is known for developing inventive solutions to some of the worlds biggest health problems, many scientists are working with manual, siloed and inefficient processes," said Jacob Lee, CEO and co-founder, Genemod. "It is crucial to invest in companies leveraging technology to provide software for scientists working on the frontlines of solving the worlds global health challenges," said Neil Sequeira, co-founder and partner, Defy.vc, "our firm believes that investing in software companies like Genemod will create incredible value in a variety of ways and rapidly solve some of the biggest impediments facing research and discovery." Alongside some of the worlds leading biotech institutions, including the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Genemods long-term vision is to enable organizations to develop cures faster by offering technologically advanced, pre-clinical software solutions.